TransMedics Group's (TMDX) "Overweight" Rating Reiterated at Piper Sandler

Piper Sandler reissued their overweight rating on shares of TransMedics Group (NASDAQ:TMDX - Free Report) in a research note published on Wednesday, Benzinga reports. The brokerage currently has a $120.00 target price on the stock, up from their prior target price of $95.00.

TMDX has been the subject of several other reports. Morgan Stanley raised their price target on TransMedics Group from $75.00 to $95.00 and gave the company an equal weight rating in a report on Wednesday, February 28th. Oppenheimer boosted their target price on shares of TransMedics Group from $105.00 to $125.00 and gave the stock an outperform rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. raised their price objective on shares of TransMedics Group from $87.00 to $105.00 and gave the company an overweight rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, TransMedics Group has an average rating of Moderate Buy and an average price target of $119.00.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX traded up $23.47 during trading on Wednesday, reaching $117.60. The company had a trading volume of 4,939,623 shares, compared to its average volume of 748,621. TransMedics Group has a fifty-two week low of $36.42 and a fifty-two week high of $124.18. The company has a debt-to-equity ratio of 3.69, a current ratio of 9.30 and a quick ratio of 8.49. The stock's fifty day moving average price is $83.85 and its 200 day moving average price is $75.92. The firm has a market capitalization of $3.85 billion, a price-to-earnings ratio of -152.73 and a beta of 1.99.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.05) by $0.40. TransMedics Group had a negative net margin of 10.36% and a negative return on equity of 2.35%. The company had revenue of $96.90 million for the quarter, compared to analysts' expectations of $83.78 million. During the same period in the previous year, the company posted ($0.08) EPS. TransMedics Group's revenue was up 132.9% compared to the same quarter last year. As a group, equities research analysts predict that TransMedics Group will post -0.14 EPS for the current year.

Insider Activity at TransMedics Group

In other TransMedics Group news, insider Tamer I. Khayal sold 736 shares of the firm's stock in a transaction dated Wednesday, February 7th. The stock was sold at an average price of $90.09, for a total value of $66,306.24. Following the transaction, the insider now directly owns 14,375 shares of the company's stock, valued at $1,295,043.75. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other TransMedics Group news, insider Tamer I. Khayal sold 736 shares of the stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $90.09, for a total value of $66,306.24. Following the completion of the sale, the insider now owns 14,375 shares of the company's stock, valued at $1,295,043.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Waleed H. Hassanein sold 4,000 shares of the business's stock in a transaction on Wednesday, April 17th. The stock was sold at an average price of $95.12, for a total transaction of $380,480.00. Following the transaction, the chief executive officer now directly owns 74,087 shares in the company, valued at $7,047,155.44. The disclosure for this sale can be found here. In the last three months, insiders have sold 117,078 shares of company stock valued at $9,972,971. Insiders own 6.70% of the company's stock.

Hedge Funds Weigh In On TransMedics Group

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. J.W. Cole Advisors Inc. bought a new stake in shares of TransMedics Group during the third quarter valued at about $929,000. Bank of New York Mellon Corp boosted its holdings in shares of TransMedics Group by 91.4% in the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company's stock valued at $41,615,000 after acquiring an additional 363,012 shares in the last quarter. Shariaportfolio Inc. acquired a new position in shares of TransMedics Group during the third quarter valued at approximately $470,000. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of TransMedics Group by 12.4% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 6,913 shares of the company's stock worth $378,000 after buying an additional 763 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in TransMedics Group by 12.8% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 14,940 shares of the company's stock worth $818,000 after acquiring an additional 1,700 shares in the last quarter. 99.67% of the stock is owned by institutional investors.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.